| Released | Contributor | Author | Title | Pages | Price |
| 30-Nov-2009 | New Constructs, LLC |
N/A
| CYTR: Risk/Reward Rating: Full Report: Cash Truth Behind the Reported Earnings | 19 |
$10 |
| 30-Nov-2009 | ValuEngine, Inc. |
N/A
| ValuEngine Detailed Valuation Report for CYTR | 13 |
$25 |
| 29-Nov-2009 | ValuEngine, Inc. |
N/A
| ValuEngine Industry Report for BIOTECHNOLOGY | 18 |
$49 |
| 28-Nov-2009 | TheStreet.com Ratings |
N/A
| TheStreet.com Ratings Stock Report For: CYTRX CORP | 5 |
$25 |
| 28-Nov-2009 | Standard & Poor's Quantitative Report |
N/A
| CytRx Corp | 6 |
$25 |
| 27-Nov-2009 | Pechala's Reports | Lubomir Pechala | CYTRX CORP (CYTR=US) 2-weeks forecast | 1 |
$10 |
| 27-Nov-2009 | Pechala's Reports | Frantisek Pechala | CYTRX CORP (CYTR=US) 12-months forecast | 1 |
$15 |
| 26-Nov-2009 | Ford Investor Services, Inc. |
N/A
| Value Graph: CYTRX -- CYTR | 1 |
$4 |
| 26-Nov-2009 | Ford Investor Services, Inc. |
N/A
| Industry Value Graph: AMAG , CYPB , CYTR , ENMD , INSV , OXGN , PARD -- DRUGS | 3 |
$4 |
| 23-Nov-2009 | Plunkett Research, Ltd. | Jack W. Plunkett | Biotech & Genetics Industry Trends, Statistics & Analysis 2010 (Summary) | 71 |
$199 |
0.30% Nasdaq 
0.01 (1.15%) 
Research Reports
